Ms. Iris Bincovich reports

INNOCAN PHARMA TO PROVIDE A CORPORATE UPDATE VIA LIVESTREAM VIDEO

Innocan Pharma Corp. will provide a corporate update to the investors community and shareholders through a YouTube live stream video on Oct. 14, 2020, at 10 a.m. EST.

The update will include a corporate presentation by Innocan's chief executive officer Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan's scientific adviser Prof. Daniel Offen.

About Innocan Pharma Corp.

The company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing cannabidoil. Innocan Israel, a wholly owned subsidiary of the company, and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive licence agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug-delivery platform based on a unique controlled-release liposome to be administrated by injection. Innocan Israel plans, together with Prof. Berenholtz, head of the laboratory of membrane and liposome research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful records in the pharmaceutical and technology sectors in Israel and globally.

We seek Safe Harbor.